Image

COronary CoLLateralization in Type 2 diabEtic Patients With Chronic Total Occlusion

COronary CoLLateralization in Type 2 diabEtic Patients With Chronic Total Occlusion

Not Recruiting
18-90 years
All
Phase N/A

Powered by AI

Overview

A severe coronary artery obstruction is a prerequisite for spontaneous collateral recruitment. The formation of coronary collateral circulation(CCC) is significantly impaired in type 2 diabetic patients with chronic total occlusion (CTO) compared with non-diabetic patients with CTO. This retrospective cohort enrolls consecutive T2DM patients who had at least one lesion with coronary angiographic total occlusion.

Description

COronary CoLLateralization in Type 2 diabEtic Patients With Chronic Total Occlusion (COLLECT) study is a single center, retrospective cohort study to investigate potential factors associated with the development of coronary collateral circulation in diabetic patients. Investigators will consecutively enroll T2DM patients who had at least one lesion with coronary angiographic total occlusion. The development of coronary collateral circulation will be graded according to the Rentrop method and patients will be divided into poor CCC (grade 0 or 1) or good (grade 2 or 3) CCC groups according to their Rentrop grades. Baseline clinical and laboratory characteristics at hospital admission will be recorded to analyze potential factors associated with the development of coronary collateral circulation in T2DM patients with CTO. Later, their cardiac function will be evaluated by echocardiography at one year follow-up.

Eligibility

Inclusion Criteria:

  • Age 18-90 years
  • Type 2 diabetes diagnosed by one of the following criteria:
        HbA1c >/= 6.5% Fasting plasma glucose >/= 7.0 mmol/l (confirmed) 2h plasma glucose value
        during OGTT >/= 11.1 mmol/l Already receiving glucose-lowering agents.
          -  At least one lesion with angiographic total occlusion
        Exclusion Criteria:
          -  eGFR<15mL/(min·1.73m2)
          -  chronic heart failure with NYHA grade ≥3
          -  had a history of coronary artery bypass grafting
          -  had received a percutaneous coronary intervention within the prior 3 months
          -  Malignant tumor or immune system disorders
          -  Pulmonary heart disease

Study details
    Chronic Total Occlusion of Coronary Artery
    Diabetes Mellitus
    Type 2

NCT06054126

Ruijin Hospital

30 March 2026

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.